EGFR and non-small cell lung carcinoma: Osimertinib, a representative third-generation anti-EGFR TKI, while exhibiting higher response rates and longer PFS than platinum-based chemotherapeutic treatment (45), has also shown efficacy in NSCLC patients with EGFR-T790M mutations after progression to treatment with first-generation TKIs (24, 46, 47).